top of page

NCCN Recommends Ropeginterferon Alfa-2b in Clinical Practice Guidelines Update

March 2022


The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology has been updated to include ropeginterferon alfa-2b (Besremi) as a recommended treatment option for adult patients with polycythemia vera. Polycythemia vera is a blood disorder characterized by the overproduction of red blood cells. The inclusion of ropeginterferon alfa-2b in the guidelines is seen as a shift toward more proactive treatment earlier in the disease journey.


The decision to recommend ropeginterferon alfa-2b is based on findings from clinical trials, including PEGINVERA, PROUD-PV, and CONTINUATION-PV. In the PEGINVERA trial, 61% of patients achieved a complete hematological response after 7.5 years of treatment with ropeginterferon alfa-2b. Most patients (80%) developed a hematological response with the agent, including normal spleen size and reduced thrombosis.


Common adverse effects of ropeginterferon alfa-2b reported in the trials included influenza-like illness, arthralgia, fatigue, pruritis, nasopharyngitis, and musculoskeletal pain. Serious adverse reactions were urinary tract infection, transient ischemic attack, and depression.


The PROUD-PV and CONTINUATION-PV trials compared ropeginterferon alfa-2b with hydroxyurea, a commonly used treatment for polycythemia vera. The results showed that ropeginterferon alfa-2b was non-inferior to hydroxyurea in achieving a complete hematological response with normal spleen size at 1 year. Furthermore, improved disease burden was observed in a higher percentage of patients treated with ropeginterferon alfa-2b compared to hydroxyurea at 36 months.


Ropeginterferon alfa-2b is approved with a boxed warning for the risk of aggravating neuropsychiatric, autoimmune, ischemic, and infectious disorders. The inclusion of ropeginterferon alfa-2b in the NCCN guidelines shortly after its approval highlights its potential in the care of polycythemia vera patients.


Source:


References


  1. NCCN clinical practice guidelines in oncology update recommends besremi (ropeginterferon alfa-2b-njft) for the treatment of polycythemia vera. News release. PharmaEssentia. March 2, 2022. Accessed March 2, 2022. https://bit.ly/3HwMNr7

  2. Besremi. Prescribing information. PharmaEssentia; 2021. Accessed March 2, 2022. https://bit.ly/3IFyj9J

  3. Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196-e208. doi:10.1016/S2352-3026(19)30236-4

Links:


 
 
 

Commentaires

Noté 0 étoile sur 5.
Pas encore de note

Ajouter une note
Global MPN Scientific Foundation Logo

Contact

Avenida Josep Tarradellas 157, 5o 2a - Barcelona, 08029 - Spain

Follow

Sign up to get the latest news on our activities and MPN news.

Thanks for subscribing!

CONTENT TRANSLATION DISCLAIMER

Please note that this website uses AI to automatically translate its content to other languages, to help people to better understand the content that we originally publish in English. While we have made every effort to ensure the accuracy of the translation, there may be some mistakes or inaccuracies. We apologize for any errors and suggest visiting the original text in English for the most accurate information.

MEDICAL DISCLAIMER

Information on this website is provided for informational purposes only and is not intended as a substitute for the advice provided by your physician or other healthcare professional. You should not use the information on this website for diagnosing or treating a health problem or disease, or prescribing any medication or other treatment.

 

Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment. Nothing contained on this website is intended to be for medical diagnosis or treatment. It should not be used in place of the advice of your physician or other qualified healthcare provider. Should you have any healthcare-related questions, please call or see your physician or other qualified healthcare provider promptly. Always consult with your physician or other qualified healthcare provider before embarking on a new treatment, diet, or fitness program. 

This website does not recommend self-management of health issues. Information obtained by using this website is not exhaustive and does not cover all diseases, ailments, physical conditions, or their treatment. Should you have any healthcare-related questions, please call or see your physician or other qualified healthcare provider promptly. You should never disregard medical advice or delay in seeking it because of something you have read here.

bottom of page